RNase Inhibitor ELISA Kit

Ribonuclease inhibitors (RNase Inhibitors, RI) are important proteins found throughout mammalian cells, especially in the cytoplasm. They make stable interactions with ribonucleases (RNases), thus hindering RNases from generating RNA degradation. RI helps regulate RNA stability and intracellular RNA integrity, thus controlling the cell's RNA lifespan. As a classic leucine-rich repeat protein, the function and mechanisms of RI have become a growing area of research. RI is a massive molecular protein that contains around 450 amino acid residues, weighs around 49 kDa, and has an isoelectric point (pI) of around 4.7. This particular structure is distinctive in that it contains significant quantities of leucine (21.5%), much more than normal proteins (9%). Additionally, RI has a relatively high cysteine content (about 6.5%), compared to the typical cysteine content of 1.7% in most proteins. The high cysteine content makes RI highly sensitive to oxidation, which impacts its function and stability. The secondary structure of RI is composed of alternating α-helices and β-strands, forming a tightly wound, horseshoe-like structure. This structure not only stabilizes the overall protein conformation but also enables strong binding to ribonucleases. RI's structure consists of multiple units of 57 amino acid residues, each encoded by different exons. RI binds to ribonucleases with a very high affinity, with a dissociation constant (Kd) in the femtomolar (fM) range, allowing it to effectively inhibit the catalytic activity of ribonucleases inside the cell.

Figure 1. Microscopic Examination of Human Cells Exposed to Ribonuclease (Source: Haigis, M.C., et al., 2003)

The binding of RI to ribonucleases is achieved through electrostatic interactions and large buried surface areas. The interaction between RI and RNase A is primarily driven by electrostatic forces, although the structural interaction is complex, the core involves tight contact between multiple amino acid residues, enhancing binding affinity. The crystal structure of the RI-RNase A complex reveals that RI interacts extensively with the active site of RNase A, completely inhibiting its RNA hydrolysis activity. Thus, RI effectively prevents the degradation of RNA inside cells by inhibiting ribonucleases. Although RI can bind with a variety of ribonucleases, its affinity varies across different types of RNases. For example, RI binds less effectively to ribonucleases from certain species, especially amphibians (such as Rana ribonuclease and Anf-1 ribonuclease), which can evade RI inhibition and show different cytotoxicity towards some cancer cells. Therefore, the inhibitory effect of RI is species-specific, which has important implications for the biological function of ribonucleases and their medical applications. Ribonucleases (RNases) and their homologs (such as bovine seminal ribonuclease and Onconase®) have cytotoxic properties, particularly in cancer treatment. These ribonucleases inhibit cellular function by degrading RNA, leading to cell death. Onconase®, a homolog of RNase A from the Northern Leopard Frog, has demonstrated anticancer and antiviral activity. However, it has raised concerns due to its toxicity to non-cancer cells, particularly kidney toxicity. Although RNase A and its variants exhibit toxicity to cells at low concentrations, the exact mechanism remains unclear. Recent studies have shown that tumor cells respond differently to variants of RNase A (such as G88R RNase A), which may be linked to these variants evading RI inhibition. The sensitivity of cells to toxic ribonucleases is closely related to the presence of RI, with cells avoiding RI binding to maintain ribonuclease activity. As such, the level of RI may determine the extent to which cells are susceptible to ribonuclease toxicity.

In mammalian cells, RI is a common cytoplasmic protein that is widely distributed across various cell types. Every cell contains RI, which plays a key role in the stability of cellular RNA and forms complexes with other members of the ribonuclease superfamily. In these complexes, RI inhibits the hydrolytic activity of ribonucleases, preventing the degradation of cellular RNA. The concentration of RI is closely linked to cellular metabolic activity and proliferation. In some tumor cell lines, the expression level of RI is increased, potentially correlating with enhanced cell division and growth rates. RI's regulation of RNA hydrolysis activity primarily depends on its affinity for and inhibitory capacity toward different ribonucleases. Studies show that higher intracellular concentrations of RI enhance resistance to the toxic effects of RNase A variants, such as the G88R mutation. This suggests that RI not only acts as a natural inhibitor of ribonucleases but may also play a role in cellular antioxidant defense and antiviral responses. RI's biological functions are not limited to RNA stability regulation; it also has potential applications in medicine. For instance, RI is associated with RNA degradation mechanisms in cancer cells, offering potential therapeutic applications in cancer treatment. By modulating the expression or function of RI, it may enhance the resistance of cells to ribonucleases, thereby inhibiting cancer cell growth. Furthermore, RI could contribute to regulating immune responses and antiviral reactions, particularly in combating certain viral infections and tumor cells. However, the function of RI may be limited in some cancer cells, primarily due to the differential mechanisms of cellular uptake of various ribonucleases and the differences in cell types. For cell-type-specific ribonuclease toxicity, RI may exert different effects, providing new avenues for clinical applications.

RNase Inhibition Detection Kit
RNase Inhibitor Activity ELISA
RNase Inhibitor Assay Kit
RNase Inhibitor Immunoassay Kit